Biocept Revenue per Share
The Revenue per Share of Biocept (BIOCQ) as of Oct 8, 2026 is 45.37 USD. In the previous year, Revenue per Share was 125.00 USD — a change of -63.71% (lower).
Get this data via API
Financial Data API
Revenue per Share
45.37USD
YoY
-63.71%
Last updated:
Revenue per Share of Biocept is 2022 45.37 USD. Revenue per Share of Biocept was 2021 125.00 USD. It decreases by -63.71% lower compared to the previous year.
The Biocept Revenue per Share history
3 Years
10 Years
25 Years
Max
Revenue per Share
Date
Revenue per Share
Jan 1, 2018
325.00 USD
Jan 1, 2019
79.00 USD
Jan 1, 2020
70.41 USD
Jan 1, 2021
125.00 USD
Jan 1, 2022
45.37 USD
Jan 1, 2023 (e)
4.47 USD
Jan 1, 2024 (e)
11.69 USD
Jan 1, 2025 (e)
38.81 USD
| YEAR | Revenue per Share | YoY |
|---|---|---|
| est | 38.81USD | +231.83% |
| est | 11.69USD | +161.41% |
| est | 4.47USD | -90.14% |
| 45.37USD | -63.71% | |
| 125.00USD | +77.53% | |
| 70.41USD | -10.87% | |
| 79.00USD | -75.69% | |
| 325.00USD | — |
Access this data via the Eulerpool API
Biocept Stock analysis
What does Biocept do? Biocept is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Biocept stock
Revenue per Share of Biocept is 45.37 USD in 2022.
Revenue per Share of Biocept changed from 125.00 USD to 45.37 USD, representing a -63.71% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Revenue per Share Biocept since 2006 – with annual values, charts, and detailed analysis.
Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.
Access this data via the Eulerpool API
Income Statement — Biocept
All Key Metrics — Biocept
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth